Prevalence and factors related to adverse reactions in the treatment of acne with isotretinoin
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2024.209603Keywords:
Acne vulgaris, Drug-related side effects and adverse reactions, Safety management, Drug therapyAbstract
Objective: To estimate the prevalence of adverse reactions with the use of the drug isotretinoin
in patients undergoing acne treatment and the characteristics related to the outcome Methods: Analytical cross-sectional observational study with secondary data obtained through the analysis of 120 medical records of patients with acne undergoing treatment with oral isotretinoin, from 2010 to 2019. Results: The mean age was 21.3 years, with similar distribution in terms of gender. The prevalence of adverse reactions was 83%, with an average of 2.3 reactions/patient. The prevalence of some type of adverse reaction to the use of isotretinoin was 82.5%. A positive correlation was found between the number of adverse reactions and the duration of treatment (p<0.0001; r=0.51). Treatment time was related to the onset of adverse reactions, regardless of gender, age, dose, and degree of acne (p=0.001). Xeroderma and dryness of mucous membranes were the most common adverse reactions (78.3%), while alopecia was more common in females, being around five times more frequent than in males (p=0.03). Conclusion: The prevalence of adverse reactions during isotretinoin use was high. The number of adverse reactions was associated only with the duration of treatment in the studied sample, regardless of gender, age, and isotretinoin dosage.
Downloads
References
Tugrul Ayanoglu B, Demirdag HG, Yalici Armagan B, Bezirgan O. Perceptions about oral isotretinoin treatment. Dermatol Ther. 2019 May;32(3):e12873. doi: 10.1111/dth.12873.
Silva AMF, Costa FP, Moreira M. Acne vulgar: diagnóstico e manejo pelo médico de família e comunidade. Rev Bras Med Fam Comunidad. 2014;9(30):54-63. doi:10.5712/rbmfc9(30)754.
Kolbe AC, Silva FL. Uso da isotretinoína no tratamento da acne e sua relação com a halitose. Rev Cienc Med Biol. 2017;16(1):101-5. doi:10.9771/cmbio.v16i1.14169.
Clark AK, Saric S, Sivamani RK. Acne scars: how do we grade them? Am J Clin Dermatol. 2018 Apr;19(2):139-44. doi:10.1007/s40257-017-0321-x.
Bagatin E, Costa CS. The use of isotretinoin for acne–an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020 Aug;13(8):885-97. doi:10.1080/17512433.2020.1796637.
Costa CS, Bagatin E, Martimbianco ALC, da Silva EM, Lúcio MM, Magin P, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev. 2018 Nov 24;11(11):CD009435. doi:10.1002/14651858.CD009435.pub2.
Andrade Júnior FP, Lima BTM, Menezes JS, Cruz JHA, Alves TWB, Oliveira Filho AA. Uso de isotretinoína por mulheres em idade reprodutiva. Arch Health Investig. 2019;8(8). doi:10.21270/archi.v8i8.3230.
Cajueiro ES, Lima LBR, Partata AK. Isotretinoína e suas propriedades farmacológicas. Rev Cient ITPAC. 2014;7(1).
Pereira WGO, Damascena RS. Avaliação dos Potenciais Efeitos Adversos em Pacientes em Uso de Isotretinoína oral para o Tratamento de Acne Vulgar: Uma Revisão Bibliográfica. ID on Line Rev Psic. 2017;11(35):42-55.
Soyuduru G, Ösoy Adışen E, Kadıoğlu Özer İ, Aksakal AB. The effect of isotretinoin on insulin resistance and adipocytokine levels in acne vulgaris patients. Turk J Med Sci. 2019 Feb 11;49(1):238-244. doi:10.3906/sag-1806-44.
Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2021 Apr;60(4):451-460. doi:10.1111/ijd.15089.
Vinhal DC, Roberth AO, Ortence VOP, Diniz DGA. Terapia retinóide na acne vulgar. Rev Eletr Farm. 2014;11(3):80-101.
Magalhães VP, Martins BCC, Cavalcante RMA, Oliveira FRP, Chaves EF, Guedes MM, et al. Avaliação das notificações de reações adversas a medicamentos em pacientes transplantados em um hospital sentinela de Fortaleza-Ceará. Rev Bras Farm Hosp Serv Saúde. 2017;8(1):22-8.
Oliveira GA, Ruas CSL, Lacerda LG, Coelho VAT, Nascimento ES. Isotretinoína no tratamento da acne: riscos e benefícios. Rev Saúde Vales. 2020;1(1).
Gonçalves AF, Santos JLOR, Biset YMCM, Rodrigues JLG. Uso indiscriminado de isotretinoína no tratamento da acne severa e seus efeitos adversos. Rev Art.com. 2021;32:e9216.
Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013 Dec;149(12):1392-8. doi:10.1001/jamadermatol.2013.6746.
Rao PK, Bhat RM, Nandakishore B, Dandakeri S, Martis J, Kamath GH. Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris. Indian J Dermatol. 2014 May;59(3):316. doi:10.4103/0019-5154.131455.
Sadeghzadeh‐Bazargan A, Ghassemi M, Goodarzi A, Roohaninasab M, Najar Nobari N, Behrangi E. Systematic review of low‐dose isotretinoin for treatment of acne vulgaris: focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021 Jan;34(1):e14438. doi:10.1111/dth.14438.
Schmitt JV, Tavares M, Cerci FB. Mulheres adultas com acne apresentam maior risco de elevação de triglicerídeos ao uso de isotr.etinoína oral. An. Bras. Dermatol. 2011;86(4):807-10. doi:10.1590/S0365-05962011000400033
Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf. 2004 Mar;3(2):119-29. doi: 10.1517/eods.3.2.119.27340.
Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010 Nov;51(4):248-53. doi:10.1111/j.1440-0960.2010.00657.x.
Landis MN. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020 Jun;21(3):411-19. doi:10.1007/s40257-020-00508-0.
Brito MFM, Sant'Anna IP, Galindo JCS, Rosendo LHPM, Santos JB. Avaliação dos efeitos adversos clínicos e alterações laboratoriais em pacientes com acne vulgar tratados com isotretinoína oral. An Bras Dermatol. 2010;85:331-7. doi:10.1590/S0365-05962010000300006
Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017 Jul;30(4). doi:10.1111/dth.12483.
İslamoğlu ZGK, Altınyazar HC. Effects of isotretinoin on the hair cycle. J Cosmet Dermatol. 2019 Apr;18(2):647-651. doi:10.1111/jocd.12800.
Hasdemir C, Sagcan A, Sekuri C, Ildizli M, Ulucan C, Ceylan C. Isotretinoin (13‐cis‐retinoic acid) associated atrial tachycardia. Pacing Clin Electrophysiol. 2005 Apr;28(4):348-9. doi:10.1111/j.1540-8159.2005.09365.x.
Bugdayci G, Polat M, Oguzman H, Cinpolat HY. Interpretation of biochemical tests using the reference change value in monitoring adverse effects of oral isotretinoin in 102 ethnic Turkish patients. Lab Med. 2016 Aug;47(3):213-9. doi:10.1093/labmed/lmw024.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Luma Miranda Souza, Mariana Moura Oliveira, David Fernandes Lima , Johnnatas Mikael Lopes, Matheus Rodrigues Lopes, Isnaia Firminia de Souza Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
